Summary: Merck is accelerating the transition of Keytruda to a subcutaneous (SC) version to extend patent life and improve patient convenience.

• Expert Insight (By BioPulse Global): "This is a classic Life Cycle Management (LCM) strategy. From a formulation perspective, achieving high-concentration protein stability while maintaining low viscosity for SC injection is the ultimate challenge in scale-up feasibility."